MX2015013172A - Metodos para determinar el pronostico de cancer colorrectal. - Google Patents

Metodos para determinar el pronostico de cancer colorrectal.

Info

Publication number
MX2015013172A
MX2015013172A MX2015013172A MX2015013172A MX2015013172A MX 2015013172 A MX2015013172 A MX 2015013172A MX 2015013172 A MX2015013172 A MX 2015013172A MX 2015013172 A MX2015013172 A MX 2015013172A MX 2015013172 A MX2015013172 A MX 2015013172A
Authority
MX
Mexico
Prior art keywords
tumor
colorectal cancer
subject
methods
panel
Prior art date
Application number
MX2015013172A
Other languages
English (en)
Other versions
MX363693B (es
Inventor
Daniel John O'shannessy
Nicholas C Nicolaides
Elizabeth B Somers
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of MX2015013172A publication Critical patent/MX2015013172A/es
Publication of MX363693B publication Critical patent/MX363693B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En la presente descripción se proporcionan métodos para determinar el riesgo de que un sujeto con diagnóstico de cáncer colorrectal desarrollará una recurrencia de cáncer colorrectal y métodos para pronosticar un resultado clínico para un sujeto con diagnóstico de cáncer colorrectal que implican a) determinar el nivel de expresión para cada marcador de un panel de marcadores en un panel de compartimentos tumorales en una muestra de tejido tumoral del sujeto, en donde el panel de marcadores comprende por lo menos dos de TEM1, HIF2a, CAIX, PDGFRß, fibronectina, colágeno I, colágeno IV y CD31, y en donde el panel de compartimentos tumorales comprende por lo menos tres compartimentos tumorales de estroma puro, tumor, vasos estromales y vasos tumorales; b) determinar el puntaje TAPPS para ese sujeto; y c) comparar el puntaje TAPPS del sujeto con el puntaje TAPPS de una población de sujetos con diagnóstico de cáncer colorrectal. Además, se proporcionan métodos relacionados implementados por computadora y sistemas, kits y micromatrices de tumores.
MX2015013172A 2013-03-15 2014-03-15 Metodos para determinar el pronostico de cancer colorrectal. MX363693B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793565P 2013-03-15 2013-03-15
PCT/US2014/029898 WO2014145181A1 (en) 2013-03-15 2014-03-15 Methods for determining prognosis of colorectal cancer

Publications (2)

Publication Number Publication Date
MX2015013172A true MX2015013172A (es) 2015-12-11
MX363693B MX363693B (es) 2019-03-29

Family

ID=51537896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013172A MX363693B (es) 2013-03-15 2014-03-15 Metodos para determinar el pronostico de cancer colorrectal.

Country Status (5)

Country Link
US (2) US9915660B2 (es)
EP (1) EP2972376B1 (es)
JP (1) JP6417602B2 (es)
MX (1) MX363693B (es)
WO (1) WO2014145181A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016205292B2 (en) * 2015-01-07 2019-02-14 Wright Medical Technology, Inc. Fixation mechanism for an implant
US10676792B2 (en) 2015-04-01 2020-06-09 The Regents Of The University Of California Prognostic and diagnostic methods for colorectal cancer
EP3481951A4 (en) * 2016-07-06 2020-08-05 Youhealth Biotech, Limited METHYLATION MARKERS FOR COLON CARCINOMA AND USES THEREOF
CN112368705A (zh) 2018-05-24 2021-02-12 匹兹堡大学高等教育联邦体系 从空间多参数细胞和亚细胞成像数据预测癌症复发

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US8068988B2 (en) 2003-09-08 2011-11-29 Ventana Medical Systems, Inc. Method for automated processing of digital images of tissue micro-arrays (TMA)
WO2005027015A2 (en) 2003-09-10 2005-03-24 Bioimagene, Inc. Method and system for quantitatively analyzing biological samples
WO2007016367A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Neoplastic disease-related methods, kits, systems and databases
ATE493652T1 (de) * 2005-08-11 2011-01-15 Siemens Healthcare Diagnostics Quantitative assays für pdgfr-beta- in körperflüssigkeiten
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
WO2008143849A2 (en) 2007-05-14 2008-11-27 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
US8067178B2 (en) * 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2012166824A2 (en) 2011-05-31 2012-12-06 Oregon Health And Science University Methods and kits that identify tumors responsive to src inhibitors
ITFI20110181A1 (it) * 2011-08-12 2013-02-13 Univ Firenze Herg1 e glut-1 in tumori colorettali.

Also Published As

Publication number Publication date
EP2972376A4 (en) 2017-02-08
JP6417602B2 (ja) 2018-11-07
EP2972376B1 (en) 2018-12-05
BR112015022085A2 (pt) 2017-07-18
EP2972376A1 (en) 2016-01-20
US10539565B2 (en) 2020-01-21
MX363693B (es) 2019-03-29
JP2016513809A (ja) 2016-05-16
WO2014145181A1 (en) 2014-09-18
WO2014145181A4 (en) 2014-11-27
US9915660B2 (en) 2018-03-13
US20180196052A1 (en) 2018-07-12
US20160003829A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
MX2017015260A (es) Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2015013172A (es) Metodos para determinar el pronostico de cancer colorrectal.
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
WO2012151390A3 (en) A therapeutic and diagnostic target gene in acute myeloid leukemia
Morhij et al. The modified Glasgow prognostic score in patients undergoing surgery for bone and soft tissue sarcoma
WO2017217807A3 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
Ozerhan et al. Fascin expression in colorectal carcinomas
WO2016161153A3 (en) Prognostic and diagnostic methods for colorectal cancer
GB201018312D0 (en) Metagene expression signature for prognosis of breast cancer patients
WO2016018524A8 (en) E2f4 signature for use in diagnosing and treating breast and bladder cancer
WO2014066860A3 (en) Methods of prognosticating and treating cancer
WO2013190468A3 (en) Computer-based predictor for prostate cancer
EA202191694A1 (ru) Панель биомаркеров для диагностики и прогнозирования рака